Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Truist Adjusts Price Target on AbbVie to $135 From $118, Maintains Buy Rating

11/24/2021 | 11:50am EST


ę MT Newswires 2021
All news about ABBVIE INC.
01/25Drugmaker Teva fueled opioid addiction in New York, jury finds
RE
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25AbbVie - Allergan Aesthetics Announces Open Casting Call for BOTOX Cosmetic
AQ
01/25Berenberg Bank Adjusts AbbVie's Price Target to $115 From $105, Maintains Hold Rating
MT
01/24Morgan Stanley Adjusts AbbVie's Price Target to $142 from $124, Keeps Overweight Rating
MT
01/24Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
AQ
01/24AbbVie - U.S. FDA Approves Second Indication for SKYRIZI (risankizumab-rzaa) to Treat A..
AQ
01/24Allergan Aesthetics Announces Open Casting Call for BOTOX« Cosmetic (onabotulinumtoxinA..
PR
01/21AbbVie Receives FDA Second Indication Approval for Skyrizi to Treat Adults with Active ..
MT
01/20Barclays Adjusts AbbVie's Price Target to $133 from $118, Keeps Equalweight Rating
MT
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 248 M - -
Net income 2021 11 140 M - -
Net Debt 2021 63 574 M - -
P/E ratio 2021 21,2x
Yield 2021 3,85%
Capitalization 240 B 240 B -
EV / Sales 2021 5,40x
EV / Sales 2022 4,86x
Nbr of Employees 50 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 135,97 $
Average target price 143,83 $
Spread / Average Target 5,78%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael CFO, Vice Chairman-Finance & Commercial Operations
Thomas J. Hudson VP, Head-Oncology Discovery & Early Development
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.0.42%240 379
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
NOVO NORDISK A/S-12.29%219 960
ELI LILLY AND COMPANY-13.89%214 609